Novartis, in partnership with Versant Ventures, has established Borealis Biosciences, a Vancouver-based biotechnology company dedicated to developing next-generation xRNA-based therapies for kidney diseases. This new entity builds on the scientific foundation laid by Chinook Therapeutics, a kidney disease-focused company acquired by Novartis in 2023. Borealis aims to leverage xRNA technology to modulate mRNA and target proteins associated with kidney diseases, potentially revolutionizing treatment options in this field.
The formation of Borealis is part of a broader strategic collaboration between Novartis and Versant Ventures, designed to accelerate renal science. The collaboration includes a unique transaction structure involving divestment, collaboration, and investment, marking a first for Novartis. The company has transferred key personnel and facilities from Chinook to Borealis, creating an environment poised for rapid drug discovery. Additionally, Novartis retains an option to acquire two future development-ready programs, aligning with its core focus on renal medicine.
Borealis Biosciences has emerged from stealth with Series A financing from both Novartis and Versant Ventures. The company's research site, a state-of-the-art facility in Vancouver, is staffed by a team of over 25 experts in kidney disease and RNA-based therapeutics. Borealis is poised to advance the field of xRNA medicine, with the goal of improving outcomes for patients with chronic kidney conditions and addressing unmet medical needs.
Click here to read the original news story.